Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.
Leukemia
Kubesova, B B; Pavlova, S S; Malcikova, J J; Kabathova, J J; Radova, L L; Tom, N N; Tichy, B B; Plevova, K K; Kantorova, B B; Fiedorova, K K; Slavikova, M M; Bystry, V V; Kissova, J J; Gisslinger, B B; Gisslinger, H H; Penka, M M; Mayer, J J; Kralovics, R R; Pospisilova, S S; Doubek, M M
Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance.
Scientific Reports
Kesarwani, Meenu M; Huber, Erika E; Kincaid, Zachary Z; Evelyn, Chris R CR; Biesiada, Jacek J; Rance, Mark M; Thapa, Mahendra B MB; Shah, Neil P NP; Meller, Jarek J; Zheng, Yi Y; Azam, Mohammad M